CAMX icon

Cambiar Aggressive Value ETF
CAMX

29.64 USD
At close Jan 10, 4:00 PM EST
1 day
0.00%
5 days
-0.97%
1 month
-2.92%
3 months
-0.10%
6 months
3.06%
Year to date
1.09%
1 year
12.66%
5 years
22.53%
10 years
22.53%
0
Funds holding %
of 6,810 funds
–
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 9 [Q2] → 9 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

1.25% less ownership

Funds ownership: 10.81% [Q2] → 9.56% (-1.25%) [Q3]

9% less capital invested

Capital invested by funds: $6.23M [Q2] → $5.66M (-$568K) [Q3]

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CAMX.

See Analyst Rankings

Financial journalist opinion

Neutral
PRNewsWire
5 months ago
Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1 ≤ 1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom and quality of life scores vs baseline Study results reinforce previously reported interim results from ACROINNOVA 21 LUND, Sweden , July 15, 2024 /PRNewswire/ -- Camurus (NASDAQ: CAMX) (STO: CAMX) today announced positive, final, topline results from the 52-week Phase 3 open-label ACROINNOVA 2 (NCT04125836) study, which evaluated safety and efficacy of the company's once-monthly octreotide subcutaneous (SC) depot (CAM2029). The study included a total of 135 patients with acromegaly who were biochemically controlled (IGF-1≤1xULN) or uncontrolled on stable doses of standard-of-care (SoC) with first generation somatostatin ligands (SRL) at screening; of these, 81 were new to study patients and 54 were roll-over patients from 24-week randomized treatment with octreotide SC depot or placebo (ACROINNOVA 1).
Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
See News Rankings
Charts implemented using Lightweight Charts™